GO:0008119 thiopurine S-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008119 defines the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to a thiopurine drug, producing S-adenosyl-L-homocysteine and a methylated thiopurine metabolite.
• TPMT is the principal human enzyme carrying this activity, and its genetic polymorphisms are a major determinant of thiopurine toxicity and dosing.
• Measurement of TPMT activity in erythrocytes is a validated clinical tool for predicting thiopurine intolerance and guiding therapy [1,4].
• TPMT activity is influenced by drug-drug interactions, and several co-administered medications can alter thiopurine metabolism.
• Beyond drug metabolism, TPMT has been linked to oxidation-reduction processes, suggesting broader cellular roles.
• Population-specific cutoffs for TPMT activity are necessary because allele frequencies and phenotype-genotype concordance vary across ethnic groups [3,7].
Description
Thiopurine S-methyltransferase (TPMT) activity, encoded by GO:0008119, is a molecular function that catalyzes the S-adenosyl-L-methionine-dependent methylation of thiopurine drugs such as azathioprine, mercaptopurine, and thioguanine. This reaction is a critical step in the inactivation of thiopurines, shunting them away from the production of cytotoxic thioguanine nucleotides. Because thiopurines are widely used in the treatment of inflammatory bowel disease, acute lymphoblastic leukemia, and autoimmune conditions, understanding TPMT activity is essential for safe and effective therapy [2,8]. The clinical importance of TPMT activity stems from its genetic polymorphism. Individuals with low or absent TPMT activity are at high risk of severe myelosuppression when treated with standard thiopurine doses, whereas those with very high activity may be undertreated [1,2]. Consequently, preemptive genotyping or phenotyping of TPMT is recommended by clinical guidelines to individualize dosing. Research into GO:0008119 spans enzymology, pharmacogenomics, and cell biology. Recent studies have explored TPMT activity in diverse populations, developed sensitive LC-MS/MS assays for its measurement, and uncovered its involvement in oxidation-reduction processes [3,4,6]. This article provides a comprehensive overview of the mechanism, genes, and research methods associated with thiopurine S-methyltransferase activity.
thiopurine S-methyltransferase activity At A Glance
| GO ID | GO:0008119 |
|---|---|
| GO term | thiopurine S-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | 6-thiopurine transmethylase activity; mercaptopurine methyltransferase activity; S-adenosyl-L-methionine:thiopurine S-methyltransferase activity; thiopurine methyltransferase activity; TPMT |
| Major function | Catalyzes the S-adenosyl-L-methionine-dependent methylation of thiopurine drugs, leading to their inactivation. |
| Reaction | S-adenosyl-L-methionine + a thiopurine = S-adenosyl-L-homocysteine + a thiopurine S-methylether. |
| Cofactor | S-adenosyl-L-methionine (SAM) serves as the methyl donor. |
| Substrates | Thiopurine drugs including azathioprine, mercaptopurine, and thioguanine. |
| Clinical relevance | TPMT activity levels guide thiopurine dosing to avoid toxicity. |
What Is GO:0008119?
Thiopurine S-methyltransferase activity (GO:0008119) is the catalysis of the reaction: S-adenosyl-L-methionine + a thiopurine = S-adenosyl-L-homocysteine + a thiopurine S-methylether. In other words, it is the enzyme activity that methylates thiopurine compounds using S-adenosyl-L-methionine as the methyl donor, thereby producing S-adenosyl-L-homocysteine and a methylated thiopurine metabolite.
Why Is thiopurine S-methyltransferase activity Important in Cell Biology?
Thiopurine S-methyltransferase activity is a key determinant of thiopurine drug response and toxicity. Because thiopurines are metabolized by TPMT, individuals with reduced enzyme activity accumulate cytotoxic thioguanine nucleotides, leading to severe myelosuppression [1,2]. Conversely, high TPMT activity can lead to subtherapeutic drug levels and treatment failure. Therefore, assessing TPMT activity is crucial for personalized medicine in patients receiving thiopurines [2,8].
• TPMT activity is a major predictor of thiopurine-induced myelosuppression.
• Clinical guidelines recommend TPMT genotyping or phenotyping before starting thiopurine therapy.
• TPMT activity varies widely among individuals due to genetic polymorphisms.
• Measurement of TPMT activity in erythrocytes is a validated surrogate for hepatic enzyme activity [1,4].
• Drug-drug interactions can modulate TPMT activity and affect thiopurine safety.
• TPMT has been implicated in oxidation-reduction processes, suggesting additional cellular roles.
• Population-specific reference ranges for TPMT activity are needed for accurate interpretation [3,7].
• TPMT genotyping is cost-effective for preventing adverse drug reactions.
What Happens During thiopurine S-methyltransferase activity?
Substrate Binding and Methyl Transfer
In simple terms: TPMT grabs a thiopurine drug and a methyl donor, then transfers the methyl group onto the drug.
The enzymatic reaction begins with the binding of S-adenosyl-L-methionine (SAM) and a thiopurine substrate to the active site of TPMT. SAM serves as the methyl donor, and the thiopurine acts as the methyl acceptor. The enzyme facilitates the transfer of the methyl group from SAM to the sulfur atom of the thiopurine, resulting in the formation of S-adenosyl-L-homocysteine (SAH) and a methylated thiopurine metabolite.
Product Release and Drug Inactivation
In simple terms: After methylation, the modified drug is released and can no longer be converted into toxic metabolites.
Following the methyl transfer, the methylated thiopurine and SAH are released from the enzyme. Methylation of thiopurines by TPMT shunts them away from the competing pathway that produces cytotoxic thioguanine nucleotides, thereby reducing drug efficacy but also limiting toxicity. This balance is critical for therapeutic outcomes.
Role in Thiopurine Metabolism
In simple terms: TPMT competes with other enzymes to determine how much active drug is produced.
Thiopurine drugs are metabolized through competing pathways. TPMT methylates thiopurines to inactive metabolites, while hypoxanthine phosphoribosyltransferase (HPRT) converts them to active thioguanine nucleotides. The relative activity of TPMT thus determines the proportion of drug that becomes cytotoxic versus inactive, directly influencing both efficacy and toxicity [1,2].
Clinical Implications of Enzyme Activity
In simple terms: The amount of TPMT enzyme a person has affects how they respond to thiopurine drugs.
Individuals with low TPMT activity are at increased risk of severe myelosuppression due to accumulation of thioguanine nucleotides, while those with high activity may not achieve therapeutic drug levels [1,2]. Therefore, pre-treatment assessment of TPMT activity is recommended to guide dosing [2,8].
Key Genes Involved in GO:0008119 thiopurine S-methyltransferase activity
The following genes and proteins are directly or indirectly involved in thiopurine S-methyltransferase activity and its clinical context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TPMT | Encodes thiopurine S-methyltransferase, the enzyme responsible for GO:0008119 activity. | Genetic polymorphisms affect enzyme activity and drug response. |
| NUDT15 | Encodes a nudix hydrolase that degrades thioguanine nucleotides; mutations cause thiopurine intolerance. | Genotyping is recommended alongside TPMT for thiopurine dosing. |
| HPRT1 | Encodes hypoxanthine phosphoribosyltransferase, which converts thiopurines to active thioguanine nucleotides. | Competes with TPMT for thiopurine metabolism. |
| ITPA | Encodes inosine triphosphatase, which affects thiopurine metabolite levels. | Polymorphisms may influence thiopurine toxicity. |
| GSTP1 | Encodes glutathione S-transferase pi, involved in drug metabolism. | May interact with thiopurine pathways. |
| ABCC4 | Encodes a multidrug resistance protein that transports thiopurine metabolites. | Affects intracellular drug concentrations. |
| SLC28A3 | Encodes a nucleoside transporter involved in thiopurine uptake. | May modulate drug response. |
| XDH | Encodes xanthine dehydrogenase, which metabolizes thiopurines. | Competes with TPMT for substrate. |
| MTHFR | Encodes methylenetetrahydrofolate reductase, influencing folate and SAM levels. | May indirectly affect TPMT activity. |
| ATIC | Encodes a bifunctional enzyme in purine biosynthesis, targeted by thiopurines. | Thiopurine metabolites inhibit ATIC. |
| IMPDH1 | Encodes inosine monophosphate dehydrogenase, involved in guanine nucleotide synthesis. | Thiopurines inhibit IMPDH. |
| GMPS | Encodes guanine monphosphate synthetase, involved in thiopurine activation. | Thiopurine metabolites target GMPS. |
| RAC1 | Small GTPase involved in cellular processes; may be affected by thiopurine metabolites. | Linked to oxidation-reduction processes. |
| NCF2 | Neutrophil cytosolic factor 2, involved in oxidative burst. | Expression may correlate with TPMT activity. |
| CYBB | Cytochrome b-245 beta chain, involved in redox processes. | Potential link to TPMT in oxidation-reduction. |
| NQO1 | NAD(P)H quinone dehydrogenase 1, a redox enzyme. | May interact with TPMT pathways. |
| TP53 | Tumor suppressor gene, often mutated in cancers treated with thiopurines. | Thiopurines used in leukemia therapy. |
| MTR | Methionine synthase, involved in folate metabolism and SAM regeneration. | May influence TPMT activity via SAM levels. |
How Is thiopurine S-methyltransferase activity Regulated?
Thiopurine S-methyltransferase activity is primarily regulated by genetic polymorphisms in the TPMT gene, which alter enzyme stability and catalytic efficiency. Additionally, drug-drug interactions can modulate TPMT activity; for example, certain medications may inhibit or induce TPMT, affecting thiopurine metabolism. Folate status and SAM availability may also influence TPMT activity indirectly. However, the exact regulatory mechanisms beyond genetics are not fully understood.
thiopurine S-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TPMT | Thiopurine-induced myelosuppression | TPMT knockout cell lines (e.g., HEK293, HepG2) to study drug sensitivity |
| NUDT15 | Thiopurine intolerance | NUDT15 knockout or point-mutation knock-in cells to assess thioguanine nucleotide levels |
| TPMT | Acute lymphoblastic leukemia | Leukemia cell lines with TPMT overexpression or knockout for drug response assays |
| TPMT | Inflammatory bowel disease | Patient-derived lymphoblastoid cell lines with defined TPMT genotypes |
| TPMT | Oxidation-reduction processes | TPMT knockout cells to measure redox markers and oxidative stress |
Thiopurine Toxicity and Myelosuppression
Reduced TPMT activity leads to accumulation of cytotoxic thioguanine nucleotides, causing severe myelosuppression in patients treated with standard thiopurine doses [1,2]. This adverse drug reaction is a major cause of treatment discontinuation and can be life-threatening.
Inflammatory Bowel Disease and Autoimmune Conditions
Thiopurines are commonly used to treat inflammatory bowel disease and autoimmune disorders. TPMT activity levels guide dosing to balance efficacy and toxicity in these patients [2,5].
Acute Lymphoblastic Leukemia
Thiopurines are a cornerstone of maintenance therapy for acute lymphoblastic leukemia. TPMT activity influences drug efficacy and toxicity, and genotyping is recommended to optimize treatment [2,8].
TPMT and Oxidation-Reduction Processes
Recent transcriptome analysis suggests that TPMT may be involved in oxidation-reduction processes, linking it to cellular redox homeostasis beyond drug metabolism. This emerging role warrants further investigation.
From thiopurine S-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TPMT loss alter thiopurine sensitivity? | TPMT knockout cell lines (e.g., HEK293, HCT116) generated by CRISPR-Cas9 |
| How do TPMT polymorphisms affect enzyme activity? | Point-mutation knock-in cell lines expressing variant TPMT alleles (e.g., TPMT*2, *3A, *3C) |
| Can we measure TPMT activity in live cells? | Knock-in of fluorescent or luminescent tags into endogenous TPMT locus |
| What is the effect of TPMT overexpression on drug resistance? | TPMT overexpression cell lines using lentiviral or CRISPR activation |
| How does TPMT interact with other metabolic genes? | CRISPR library screening in thiopurine-treated cells to identify synthetic lethal interactions |
| What are the off-target effects of thiopurines? | Genome-wide CRISPR knockout screens followed by thiopurine treatment and sequencing |
How to Study the thiopurine S-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | TPMT enzyme activity by quantifying methylated thiopurine metabolites | Clinical phenotyping of TPMT activity in erythrocytes |
| Radiochemical assay | TPMT activity using radiolabeled SAM | Research and clinical studies of TPMT phenotype |
| Genotyping (PCR, sequencing) | TPMT and NUDT15 variant alleles | Preemptive pharmacogenomic testing |
| RNA-seq | Global transcriptome changes associated with TPMT activity | Discovery of novel pathways involving TPMT |
| CRISPR knockout screening | Genes affecting thiopurine sensitivity | Identification of drug response modifiers |
| Western blot | TPMT protein expression levels | Validation of knockout or overexpression models |
| Enzyme-linked immunosorbent assay (ELISA) | TPMT protein concentration | Quantification in cell lysates |
| High-performance liquid chromatography (HPLC) | Thiopurine metabolite levels | Monitoring drug metabolism in patients |
Enzyme Activity Assays
TPMT activity is traditionally measured in erythrocytes using radiochemical or HPLC-based assays that quantify the conversion of 6-mercaptopurine to 6-methylmercaptopurine. More recently, LC-MS/MS methods have been developed for sensitive and specific determination of TPMT activity in human erythrocytes.
Genotyping and Phenotyping
TPMT genotyping identifies common variant alleles (e.g., TPMT*2, *3A, *3C) that reduce enzyme activity. Phenotyping directly measures enzyme activity in red blood cells and can capture rare variants and non-genetic factors [1,3]. Population-specific cutoffs are necessary for accurate classification [3,7].
Transcriptome and Pathway Analysis
RNA sequencing and transcriptome analysis can reveal global gene expression changes associated with TPMT activity, such as its involvement in oxidation-reduction processes. Such studies help uncover novel cellular roles of TPMT beyond drug metabolism.
CRISPR Screening for Drug Response
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to thiopurines, including TPMT and NUDT15. These screens provide unbiased insights into pathways affecting drug efficacy and toxicity.
How CRISPR Can Be Used to Study GO:0008119 thiopurine S-methyltransferase activity
Knockout
CRISPR-Cas9 knockout of TPMT in cell lines (e.g., HEK293, HCT116) creates models with absent enzyme activity, useful for studying thiopurine sensitivity and toxicity. These models can confirm the role of TPMT in drug inactivation and identify compensatory pathways.
Point Mutation
Introducing specific TPMT variants (e.g., TPMT*2, *3A, *3C) via CRISPR-mediated homology-directed repair allows researchers to study the functional impact of individual polymorphisms on enzyme activity and drug response. Such models mimic human genotypes and are valuable for pharmacogenomic research.
Knock-in
Knock-in of reporter tags (e.g., FLAG, GFP) into the endogenous TPMT locus enables real-time monitoring of TPMT expression and localization. This approach can also be used to create cell lines expressing TPMT under its native promoter for physiological studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of TPMT can generate cell lines with elevated enzyme activity, useful for studying the effects of high TPMT activity on thiopurine resistance and metabolism. These models help define the upper limit of enzyme activity in drug response.
How EDITGENE Supports thiopurine S-methyltransferase activity Research
Researchers studying thiopurine S-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in drug metabolism, toxicity, or cellular redox processes. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models, enabling functional validation of genes like TPMT and NUDT15 in relevant biological contexts.
Contact EDITGENE today to design your custom CRISPR model for thiopurine S-methyltransferase activity research.
Frequently Asked Questions About thiopurine S-methyltransferase activity
What is thiopurine S-methyltransferase activity?
Thiopurine S-methyltransferase activity (GO:0008119) is the enzyme activity that catalyzes the methylation of thiopurine drugs using S-adenosyl-L-methionine as a methyl donor, producing S-adenosyl-L-homocysteine and a methylated thiopurine metabolite.
What genes are involved in thiopurine S-methyltransferase activity?
The primary gene is TPMT, which encodes the enzyme thiopurine S-methyltransferase. Other genes such as NUDT15, HPRT1, and ITPA also influence thiopurine metabolism and response [2,5].
How is TPMT activity measured?
TPMT activity is typically measured in erythrocytes using radiochemical, HPLC, or LC-MS/MS assays that quantify the conversion of thiopurine substrates to methylated metabolites [1,4].
Why is TPMT activity important for drug dosing?
TPMT activity determines how quickly thiopurine drugs are inactivated. Low activity leads to accumulation of cytotoxic metabolites and increased risk of myelosuppression, while high activity may reduce efficacy. Dosing guidelines recommend adjusting thiopurine doses based on TPMT genotype or phenotype.
What are the common TPMT variants?
Common TPMT variants include TPMT*2, TPMT*3A, and TPMT*3C, which are associated with reduced enzyme activity. These variants are found at different frequencies across populations [2,7].
Can TPMT activity be affected by other drugs?
Yes, drug-drug interactions can modulate TPMT activity. For example, certain medications may inhibit or induce TPMT, affecting thiopurine metabolism and safety.
What diseases are associated with TPMT activity?
Altered TPMT activity is associated with thiopurine-induced myelosuppression, inflammatory bowel disease, autoimmune conditions, and acute lymphoblastic leukemia [1,2,8].
How does TPMT activity relate to oxidation-reduction processes?
Recent transcriptome analysis suggests that TPMT may be involved in oxidation-reduction processes, linking it to cellular redox homeostasis beyond drug metabolism.
What are the population-specific cutoffs for TPMT activity?
TPMT activity cutoffs vary by population due to differences in allele frequencies and phenotype-genotype concordance. For example, a study in the Thai population established specific cutoffs for classifying low, intermediate, and high activity.
What CRISPR models are available for studying TPMT activity?
CRISPR knockout, point mutation knock-in, tagged knock-in, and overexpression models can be generated to study TPMT function, drug response, and toxicity. EDITGENE provides these services [2,4].
Conclusion
Thiopurine S-methyltransferase activity (GO:0008119) is a critical molecular function in drug metabolism, with profound implications for thiopurine therapy. Understanding its genetic and phenotypic variability is essential for personalized medicine. Continued research using advanced CRISPR models and high-throughput methods will further elucidate its roles in health and disease.
References
- 1. Booth RA et al.. 2011. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review.. Ann Intern Med 154(12):814-23, W-295-8 PMID: 21690596
- 2. Relling MV et al.. 2019. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.. Clin Pharmacol Ther 105(5):1095-1105 PMID: 30447069
- 3. Jinda P et al.. 2026. Thiopurine S-methyltransferase (TPMT) activity cutoffs in the Thai population.. Ann Clin Biochem 63(3):240-249 PMID: 40919916
- 4. Li L et al.. 2024. Determination of Thiopurine S-Methyltransferase (TPMT) Activity in Human Erythrocytes by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).. Methods Mol Biol 2737:465-472 PMID: 38036847
- 5. Urbančič D et al.. 2025. Thiopurine S-methyltransferase - An important intersection of drug-drug interactions in thiopurine treatment.. Biomed Pharmacother 184:117893 PMID: 39923408
- 6. Šmid A et al.. 2024. Transcriptome analysis reveals involvement of thiopurine S-methyltransferase in oxidation-reduction processes.. Eur J Pharm Sci 192:106616 PMID: 37865284
- 7. Souissi S et al.. 2025. Assessment of thiopurine S-methyltransferase allele frequencies and phenotype-genotype concordance in a Tunisian population.. Drug Metab Pers Ther 40(3):151-156 PMID: 40441128
- 8. Corominas H et al.. 2004. Clinical utility of thiopurine S-methyltransferase genotyping.. Am J Pharmacogenomics 4(1):1-8 PMID: 14987117
